MBX Biosciences, Inc. (NYSE:MBX – Get Free Report) traded up 4.6% on Wednesday . The stock traded as high as $23.53 and last traded at $22.85. 15,491 shares changed hands during mid-day trading, a decline of 89% from the average session volume of 144,100 shares. The stock had previously closed at $21.85.
Analyst Upgrades and Downgrades
Several equities research analysts have weighed in on the company. Jefferies Financial Group assumed coverage on MBX Biosciences in a report on Tuesday. They issued a “buy” rating and a $35.00 price target for the company. Guggenheim assumed coverage on MBX Biosciences in a report on Tuesday. They issued a “buy” rating and a $44.00 price target for the company. Stifel Nicolaus assumed coverage on MBX Biosciences in a research note on Tuesday. They issued a “buy” rating and a $40.00 price objective for the company. Finally, JPMorgan Chase & Co. assumed coverage on MBX Biosciences in a research note on Tuesday. They issued an “overweight” rating and a $30.00 price objective for the company.
Read Our Latest Stock Analysis on MBX Biosciences
MBX Biosciences Trading Up 8.7 %
Insider Buying and Selling
About MBX Biosciences
MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.
See Also
- Five stocks we like better than MBX Biosciences
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- 3 Momentum Trades for October With Ample Upside Ahead
- The Most Important Warren Buffett Stock for Investors: His Own
- Roblox Dips on Short Report—Here’s Why It Could Bounce Back Fast
- Russell 2000 Index, How Investors Use it For Profitable Trading
- 2 Reasons to Jump on Apple Stock Now and 1 Reason to Think Twice
Receive News & Ratings for MBX Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MBX Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.